OncLive® speaks with Drs. Toni Choueiri and Peter Van Veldhuizen on the latest studies in renal cell carcinoma that were presented during the 2022 Genitourinary Cancers Symposium.
Peter J. Van Veldhuizen, MD
Advertisement
Articles by Peter J. Van Veldhuizen, MD
Peter J. Van Veldhuizen, MD, hematologist/oncologist, Sarah Cannon Research Institute, discusses combination therapy for the treatment of patients with renal cell carcinoma.
Peter J. Van Veldhuizen, MD, hematologist/oncologist, Sarah Cannon Research Institute, discusses frontline immunotherapy for the treatment of patients with kidney cancer.
Peter J. Van Veldhuizen, MD, hematologist/oncologist, Sarah Cannon Research Institute, discusses the impact of the CARMENA trial results in renal cell carcinoma.
Peter J. Van Veldhuizen, MD, hematologist/oncologist, Sarah Cannon Research Institute, discusses the frontline combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) in the treatment of patients with kidney cancer.
Advertisement
Latest Updated Articles
Dr. Van Veldhuizen on the Combination of Atezolizumab and Bevacizumab in Kidney CancerPublished: July 13th 2018 | Updated:
Dr. Van Veldhuizen Reflects on the CARMENA Trial in RCCPublished: August 20th 2018 | Updated:
Dr. Van Veldhuizen on Frontline Immunotherapy for Kidney CancerPublished: September 7th 2018 | Updated:
Dr. Van Veldhuizen Discusses Combination Therapy in RCCPublished: September 19th 2018 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma
4
Ixazomib-Containing Combinations Signal Potential for More PI-Based Regimens in R/R Multiple Myeloma
5